# EDGAR Filing Document

**Accession Number:** 0001130166
**File Stem:** 0000000000-25-007839
**Filing Date:** 2025-7
**Character Count:** 3090
**Document Hash:** 1e608d059483cecd17cd3b1a8cbe3a5d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007839.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0000000000-25-007839

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250725

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bio Green Med Solution, Inc.
- **CENTRAL INDEX KEY:** 0001130166
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911766850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08149

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 908-517-7330

**MAIL ADDRESS:**
- **STREET 1:** 200 CONNELL DRIVE
- **STREET 2:** SUITE 1500
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cyclacel Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20060329

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCYTE THERAPIES INC
- **DATE OF NAME CHANGE:** 20001218
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-016944

## Text-Extract

```

                                                            July 25, 2025

Datuk Dr. Doris Wong Sing Ee
Chief Executive Officer
Cyclacel Pharmaceuticals, Inc.
Level 10, Tower 11, Avenue 5, The Horizon
Bangsar South City, No. 8, Jalan Kerinchi
59200, Kuala Lumpur, Malaysia

       Re: Cyclacel Pharmaceuticals, Inc.
           Registration Statement on Form S-1
           Filed July 24, 2025
           File No. 333-288911
Dear Datuk Dr. Doris Wong Sing Ee:

     We have reviewed your amended registration statement and have the
following
comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our July 7, 2025
letter.

Registration Statement on Form S-1 filed July 24, 2025
General

1.     We note your response to prior comment 1 and reissue in part. You do not
appear to
       have revised your registration statement to include the pro forma
financial information
       required by Rule 8-05 of Regulation S-X, as your response indicates.
Please revise
       accordingly, or advise.
       Please contact Jason Drory at 202-551-8342 or Laura Crotty at
202-551-7614 with
any other questions.
 July 25, 2025
Page 2

                    Sincerely,

                    Division of Corporation Finance
                    Office of Life Sciences
cc:   Debbie Klis

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._